High prevalence of ceftazidime-resistant Klebsiell...[Yonsei Med J. 2006]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Yonsei Med J. 2006 Oct 31;47(5):634-45. Links

High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.

Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ, Yong D, Chong Y; KONSAR Group.

Department of Laboratory Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. whonetkor@yumc.yonsei.ac.kr

A nationwide antimicrobial resistance surveillance has been conducted since 1997 in Korea. In this study, susceptibility test data generated in 2004 by KONSAR group hospitals were analyzed and compared to those at a commercial laboratory. In hospitals, the rank orders of organisms in 2004 were identical to those in 2003. The most prevalent species was Staphylococcus aureus (20.2%) in hospitals, but Escherichia coli (29.7%) in the commercial laboratory. The proportions of Enterococcus faecium to all isolates of Enterococcus faecalis plus E. faecium were 47.2% in hospitals and 24.9% in the commercial laboratory. The mean resistance rates of significant antimicrobial-organism combinations in hospitals were: oxacillin-resistant S. aureus (68%), oxacillin-resistant (penicillin- nonsusceptible) Streptococcus pneumoniae (68%), vancomycin-resistant E. faecium (25%), cefotaxime-resistant E. coli (14%), ceftazidime- and cefoxitin-resistant Klebsiella pneumoniae (34% and 32%, respectively), and imipenem-resistant Acinetobacter spp. and Pseudomonas aeruginosa (17% and 24%, respectively). In conclusion, oxacillin-resistant staphylococci, expanded-spectrum cephalosporin-resistant K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa were prevalent in 2004. Increasing trends were observed for vancomycin-resistant E. faecium, cefoxitin- resistant E. coli and K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa. Certain antimicrobial- organism combinations were also prevalent among the commercial laboratory-tested strains.

PMID: 17066507 [PubMed - indexed for MEDLINE]

PMCID: PMC2687749

Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.
Yonsei Med J. 2006 Feb 28; 47(1):43-54.

[Yonsei Med J. 2006]
Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002.
Yonsei Med J. 2004 Aug 31; 45(4):598-608.

[Yonsei Med J. 2004]
Increasing prevalence of vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aeruginosa in Korea: KONSAR study in 2001.
J Korean Med Sci. 2004 Feb; 19(1):8-14.

[J Korean Med Sci. 2004]
Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
J Korean Med Sci. 2001 Jun; 16(3):262-70.

[J Korean Med Sci. 2001]
Korean nationwide surveillance of antimicrobial resistance in 2000 with special reference to vancomycin resistance in enterococci, and expanded-spectrum cephalosporin and imipenem resistance in gram-negative bacilli.
Yonsei Med J. 2003 Aug 30; 44(4):571-8.

[Yonsei Med J. 2003]
» See reviews... | » See all...

Cited by 3 PubMed Central articles

Metallo-beta-lactamase-producing Pseudomonas spp. in Korea: high prevalence of isolates with VIM-2 type and emergence of isolates with IMP-1 type.
Lee K, Park AJ, Kim MY, Lee HJ, Cho JH, Kang JO, Yong D, Chong Y, KONSAR group. Yonsei Med J. 2009 Jun 30; 50(3):335-9. Epub 2009 Jun 23.

[Yonsei Med J. 2009]
ReviewAcinetobacter baumannii: emergence of a successful pathogen.
Peleg AY, Seifert H, Paterson DL. Clin Microbiol Rev. 2008 Jul; 21(3):538-82.

[Clin Microbiol Rev. 2008]
Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, Lee WG, Lee HS, Chang CL, Kim SH, et al. Yonsei Med J. 2007 Oct 31; 48(5):779-86.

[Yonsei Med J. 2007]

Patient Drug Information

Vancomycin (Vancocin® )
Vancomycin is used to treat colitis (inflammation of the intestine caused by certain bacteria) that may occur after antibiotic treatment. Vancomycin is in a class of medications called glycopeptide antibiotics. It works ...
Source: AHFS Consumer Medication Information

Recent Activity

Clear Turn Off Turn On

High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-re...High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.

Related articles

Cited by 3 PubMed Central articles

Patient Drug Information

Recent Activity